SCM
CHRS icon

Suvretta Capital Management’s Coherus Oncology CHRS Stock Holding History

Suvretta Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,218,792
Closed -$19.5M – 93
2021
Q4 		$19.5M Buy
1,218,792
+729,459
+149% +$12.8M 0.38% 52
2021
Q3 		$7.86M Buy
+489,333
New +$7.17M 0.13% 71
2020
Q4 		– Sell
-238,100
Closed -$4.37M – 110
2020
Q3 		$4.37M Buy
238,100
+56,800
+31% +$1.06M 0.08% 66
2020
Q2 		$3.24M Buy
181,300
+100,000
+123% +$1.69M 0.07% 59
2020
Q1 		$1.32M Buy
+81,300
New +$1.5M 0.04% 45

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Suvretta Capital Management's CHRS Position: Q1 2022 in Review

Suvretta Capital Management sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 1,218,792 shares — an estimated $19.5M sold.

Suvretta Capital Management first reported a position in CHRS in Q1 2020 and held it in 5 quarters. The position peaked at $19.5M in Q4 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Suvretta Capital Management reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
  • Suvretta Capital Management sold 1,218,792 Coherus Oncology shares in Q1 2022, an estimated $19.5M.
  • Suvretta Capital Management first reported a position in Coherus Oncology in Q1 2020 and held it in 5 quarters.
  • Suvretta Capital Management's Coherus Oncology position peaked at $19.5M in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Suvretta Capital Management's 13F filing for Q1 2022, filed 16 May 2022.